Skip to main content

John Milad

Partner & Co-Head of Healthcare Ventures
Healthcare Ventures

John E Milad joined Downing as a Partner in January 2023 and is Co-Head of Healthcare Ventures. John has 25 years’ experience as a start-up executive, board member, venture capital investor and investment banker specialising in the life sciences sector across the UK, Europe and the USA.

‍John helped create Quanta Dialysis Technologies as an industrial spin-out from IMI plc in 2009 as an investor and founding board member. From 2014, he served as Quanta’s CEO for eight years, where he transformed the company from an early-stage UK R&D team to an emerging global leader with transatlantic operations, a world-class team and an award-winning, portable haemodialysis system poised for market disruption. During his tenure, Quanta commercially launched its offering in the UK and US markets, while raising nearly $400 million in funding and securing the prestigious MacRobert Award for engineering excellence.

‍Prior to joining Quanta, John was an Investment Director at NBGI Ventures, where both as a board member and an investor he was closely involved with a range of innovative medical technology companies in Europe and the US. Before that, John was an executive at the venture-backed start-up Nitec Pharma, an investment professional at Atlas Venture and Kirkland Investors, and an investment banker at Nomura and Lehman Brothers.

John is a graduate of the University of Chicago and previously served on the i4i selection panel for translational research at the National Institute for Health and Care Research (NIHR). He currently serves as an independent Board member at Otivio AS and is a mentor at the Enterprise Hub of the Royal Academy of Engineering.

Downing LLP
Sessions
Panel: 10:25 – 11:20

Leveraging the power of technology to disrupt health care

This panel will explore emerging areas of health tech that offer some of the biggest opportunities for investors. From what exciting technologies are converging to what new innovations have the potential to disrupt the UK health care industry, this panel will delve into everything from what challenges the sector faces, future predictions for the sector, where they’re investing and more.